ACADIA Pharmaceuticals Inc.
07/30/2026 | Press release | Distributed by Public on 07/30/2026 16:03
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference
SAN DIEGO-(BUSINESS WIRE)- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at 1:30 p.m. Eastern Time.
Live webcasts will be accessible on the company's website, acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following each presentation.
About Acadia Pharmaceuticals
Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we're here to be their difference. For more information, visit us at acadia.com and follow us on LinkedIn and X.
Investor Contact:
Acadia Pharmaceuticals Inc.
Al Kildani
(858) 261-2872
[email protected]
Acadia Pharmaceuticals Inc.
Jessica Tieszen
(858) 261-2950
[email protected]
ACADIA Pharmaceuticals Inc. published this content on July 30, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on July 30, 2026 at 22:03 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]